{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:48:29Z","timestamp":1787024909974,"version":"build-2736575974"},"reference-count":66,"publisher":"Informa UK Limited","issue":"20","funder":[{"name":"institution from Astellas Pharma and consulting fees from AbbVie and CTI Biopharma"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.2217\/fon-2022-0276","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T05:03:09Z","timestamp":1653282189000},"page":"2559-2571","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Momelotinib for the treatment of myelofibrosis with anemia"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-7192","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute,Icahn School of Medicine at Mount Sinai,\rNew York, NY,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-7972","authenticated-orcid":false,"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"UT Health San Antonio Cancer Center,\rSan Antonio, TX,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02609.x"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13005"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000001"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.02.016"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031831"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151449"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01261-x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06142.x"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000097463"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.300"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-287417"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23505"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740092"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_3_3_25_1","unstructured":"Sierra Oncology . Sierra oncology announces momelotinib achieved statistically significant benefit on symptoms anemia and splenic size in the pivotal MOMENTUM study for myelofibrosis. (2022). https:\/\/investor.sierraoncology.com\/news-releases\/news-details\/2022\/Sierra-Oncology-Announces-Momelotinib-Achieved-Statistically-Significant-Benefit-on-Symptoms-Anemia-and-Splenic-Size-in-the-Pivotal-MOMENTUM-Study-for-Myelofibrosis\/default.aspx"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01157-4"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1048"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.71"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.330"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148924"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002662"},{"key":"e_1_3_3_32_1","unstructured":"Sierra Oncology . MOMENTUM pivotal phase 3 topline results for momelotinib in myelofibrosis. https:\/\/investor.sierraoncology.com\/news-releases\/news-details\/2022\/Sierra-Oncology-Updates-Topline-Data-Timing-for-Pivotal-Phase-3-Trial-of-Momelotinib-in-Myelofibrosis\/default.aspx"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24442"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2014.10.013"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-196908000-00004"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23406"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008922200"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-339952"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104742"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18044"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-027631"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.50"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223727"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135872"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0157"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.05.012"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25777"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279415"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135880"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.01.008"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-876888"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3512"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122546"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18057"},{"key":"e_1_3_3_56_1","first-page":"Abstract 56","article-title":"CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as \u2018add-on\u2019 to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: update of MANIFEST phase 2 study","author":"Verstovsek S","year":"2020","unstructured":"Verstovsek S , MascarenhasJ, KremyanskayaMet al. CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as \u2018add-on\u2019 to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: update of MANIFEST phase 2 study. ASH Annual MeetingAbstract 56 (2020).","journal-title":"ASH Annual Meeting"},{"key":"e_1_3_3_57_1","first-page":"Abstract 55","article-title":"CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naive myelofibrosis patients: update of MANIFEST phase 2 Study","author":"Mascarenhas J","year":"2020","unstructured":"Mascarenhas J , HarrisonC, PatriarcaAet al. CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naive myelofibrosis patients: update of MANIFEST phase 2 Study. ASH Annual MeetingAbstract 55 (2020).","journal-title":"ASH Annual Meeting"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02188"},{"key":"e_1_3_3_59_1","first-page":"Abstract S216","article-title":"Addition of parsaclisib, a PI3KDELTA inhibitor, in patients (pts) with suboptimal response to ruxolitinib (RUX): a phase 2 study in pts with myelofibrosis (MF)","author":"Yacoub A","year":"2020","unstructured":"Yacoub A , WangE, RampalRet al. Addition of parsaclisib, a PI3KDELTA inhibitor, in patients (pts) with suboptimal response to ruxolitinib (RUX): a phase 2 study in pts with myelofibrosis (MF). EHA Annual MeetingAbstract S216 (2020).","journal-title":"EHA Annual Meeting"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2021.2015320"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13262"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1741381"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3194-4"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-783225"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32664"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135872"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02864"},{"key":"e_1_3_3_68_1","first-page":"S203","article-title":"Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis (MF) therapy and after prior ruxolitinib (RUX): results from the jakarta and jakarta2 trials","volume":"5","author":"Harrison C","year":"2021","unstructured":"Harrison C , KiladjianJ, VerstovsekS. Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis (MF) therapy and after prior ruxolitinib (RUX): results from the jakarta and jakarta2 trials. Hemasphere5, S203 (2021).","journal-title":"Hemasphere"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:46:08Z","timestamp":1719110768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":66,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.2217\/fon-2022-0276"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0276","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}